Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults

Vaccine

Volumn 25, Issue 3, 2007, Pages 450-457

  Halperin, Scott A ^a   Langley, Joanne M ^a   Smith, Bruce ^a   Wunderli, Peter ^b   Kaufman, Lisa ^b   Kimura, Alan ^b   Martin, Denis ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b GLAXOSMITHKLINE   (Canada)

Author keywords

Meninogococcal vaccine; Neisseria meningitidis; Outer membrane protein

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIUM ANTIBODY; DETERGENT; EMPIGEN; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL SURFACE PROTEIN A; PLACEBO; POLYSACCHARIDE VACCINE; RECOMBINANT VACCINE; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; TRITON X 100; TYLOXAPOL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERICIDAL ACTIVITY; BACTERIUM DETECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; FATIGUE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MONKEY; MOTION; NEISSERIA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; VACCINES, SYNTHETIC;

EID: 33845201825     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.001     Document Type: Article

References (28)

1. Lepow M.L., Goldschneider I., Gold R., Randolph M., and Gotschlich E.C. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 60 (1977) 673-680
2. Gold R., Lepow M.L., Goldschneider I., and Gotschlich EC. Immune response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 136 Suppl (1977) S31-S35
3. Gold R., Lepow M.L., Goldschneider I., Draper T.F., and Gotshlich E.C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 140 (1979) 690-697
4. Mitchell L.A., Ochnio J.J., Glover C., Lee A.Y., Ho M.K., and Bell A. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. J Infect Dis 173 (1996) 1009-1013
5. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 181 (2000) 761-764
6. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126 (1972) 514-521
7. Finne J., Leinonen M., and Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2 8346 (1983) 355-357
8. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., and Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10 (1992) 691-698
9. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
10. American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 2005;116:496-505.
11. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 (1991) 195-207
12. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 (1991) 1093-1096
13. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 (2005) 2191-2196
14. Martin D., Cadieux N., Hamel J., and Brodeur B.R. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185 (1997) 1173-1183
15. Cadieux N., Plante M., Rioux C.R., Hamel J., Brodeur B.R., and Martin D. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 67 (1999) 4955-4959
16. Martin D., Brodeur B.R., Hamel J., Couture F., de Alwis U., Lian Z., et al. Candidate Neisseria meningitidis NspA vaccine. J Biotechnol 83 (2000) 27-31
17. Nault A., Bonapace S., Masi D., Bouliane S., and Wunderli P. Immunogenicity and potency of rNspA vaccines in mice, an indication of stability. 12th international pathogenic Neisseria conference. Galveston, TX (2000) [Abstract #127]
18. Bouliane S., Bonapace S., Masi D., Clay M., and Wunderli P. Effect of bacterial growth conditions on specificity in the mouse serum bactericidal assay for Neisseria meningitidis. 12th international pathogenic Neisseria conference. Galveston, TX (2000) [Abstract #59]
19. Cassidy W.M., Watson B., Ioli V.A., Williams K., Bird S., and West D.J. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107 (2001) 626-631
20. Vandeputte-Rutten L., Bos M.P., Tommassen J., and Gros P. Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem 278 (2003) 24825-24830
21. Hoogerhout P., Donders E.M., van Gaans-van den Brink J.A., Kuipers B., Brugghe H.F., van Unen L.M., et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect Immun 63 (1995) 3473-3478
22. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 93 (2004) 273-282
23. Norheim G., Aase A., Caugant D.A., Hoiby E.A., Fritzsonn E., Tangen T., et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 23 (2005) 3762-3774
24. O'Dwyer C.A., Reddin K., Martin D., Taylor S.C., Gorringe A.R., Hudson M.J., et al. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 72 (2004) 6511-6518
25. Humphries H.E., Williams J.N., Blackstone R., Jolley K.A., Yuen H.M., Christodoulides M., et al. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 24 (2006) 36-44
26. Hou V.C., Moe G.R., Raad Z., Wuorimaa T., and Granoff D.M. Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71 (2003) 6844-6849
27. Martin D., Rioux S., Cloutier E., Leblanc G., Carbonneau J., Hamel J., et al. Recombinant NspA incorporated into liposomal vesicles induces functional antibodies. 13th international pathogenic Neisseria conference. Oslo, Norway (2002)
28. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 (1969) 1307-1326